ArQule (ARQL) Reaches New 52-Week High at $1.69
Shares of ArQule, Inc. (NASDAQ:ARQL) hit a new 52-week high during trading on Thursday . The company traded as high as $1.69 and last traded at $1.67, with a volume of 93900 shares. The stock had previously closed at $1.67.
ARQL has been the subject of a number of research analyst reports. ValuEngine lowered shares of ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research lowered shares of ArQule from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th.
The stock has a market capitalization of $145.47, a P/E ratio of -4.12 and a beta of 1.38. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.45 and a quick ratio of 3.45.
ArQule (NASDAQ:ARQL) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. During the same quarter in the prior year, the business earned ($0.08) earnings per share. research analysts anticipate that ArQule, Inc. will post -0.39 earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in ARQL. Northern Trust Corp grew its position in ArQule by 0.9% during the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,385 shares during the period. Curbstone Financial Management Corp grew its position in ArQule by 100.0% during the third quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock valued at $116,000 after buying an additional 52,286 shares during the period. First Eagle Investment Management LLC grew its position in ArQule by 5.0% during the third quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock valued at $13,807,000 after buying an additional 591,421 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in ArQule during the third quarter valued at approximately $2,220,000. Hedge funds and other institutional investors own 52.12% of the company’s stock.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.